Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Worst Case Scenario: Supreme Court Might Defer To It On Biosimilars

Executive Summary

During oral arguments in Sandoz v Amgen, justices suggest FDA issue rule-making on whether biosimilar sponsors can give early notification of launches and need to follow all the steps in the patent dance. The agency has explicitly said it wants to be left out of it.

You may also be interested in...



Amgen v. Sandoz: Next Biosimilar Bout Begins Over State Law Claims

In the ongoing Zarxio dispute, US appeals court takes up question left open by Supreme Court as to whether innovator company can seek remedy under state law if a biosimilar sponsor does not engage in the "patent dance" by providing its application and manufacturing information.

Amgen v. Sandoz: Next Biosimilar Bout Begins Over State Law Claims

In the ongoing Zarxio dispute, US appeals court takes up question left open by Supreme Court as to whether innovator company can seek remedy under state law if a biosimilar sponsor does not engage in the "patent dance" by providing its application and manufacturing information.

US Supreme Court Permits Earlier Biosimilar Launches; Penalty For Declining Patent Dance Uncertain

Court says biosimilar sponsors may provide 180-day notice of marketing prior to FDA approval; Federal Circuit to decide if innovators can seek an injunction under state law if sponsors do not provide application and manufacturing information; Justice Breyer offers FDA invitation to weigh in.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel